×
0 0 0 0 0 0 0 0
Stock impact report

Akcea Therapeutics: How To Profit On The Waylivra CRL? [Seeking Alpha]

Akcea Therapeutics, Inc (AKCA)  More Company Research Source: Seeking Alpha
Last akcea therapeutics, inc earnings: 8/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF Summary Always take the high road, it's far less crowded. - Charlie Munger Akcea Therapeutics (NASDAQ: AKCA ) is an RNA therapeutic innovator that has multiple powerful catalysts. The company recently gained an EU approval of its lead molecule (Tegsedi) only to witness a negative regulatory binary event later. A brief look at the long-term chart showed that the stock has many peaks and troughs. Nevertheless, the overall trend is northbound. In the past 52 weeks, the stock added $13.04 to currently exchanging hands at $33.12 for over 66.5% profits. The uptrend is reflective of the strong underlying fundamentals powering Akcea. Figure 1a: Akcea long-term chart (Source: Finviz ) An assessment of the short-term chart that is powered by the intelligence of Goruupro (a novel school of technical analysis founded by Keith Cwiok) indicated a bearish pattern in the immediate term. The immediate downtrend correlated with the negative regulatory binary for [Read more]
Impact snapshot Event time: AKCA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
AKCA alerts

from News Quantified
Opt-in for
AKCA alerts

from News Quantified